InvestorsHub Logo
Followers 3
Posts 873
Boards Moderated 0
Alias Born 02/07/2016

Re: biotechinvestor1 post# 7019

Monday, 03/28/2022 11:01:03 AM

Monday, March 28, 2022 11:01:03 AM

Post# of 8786
Nivolumab (Opdivo) is a huge BMS franchise. Its indications are growing (see the FDA approval I posted for its IV version for Melanoma just last week). As its indications and market grow, BMS is quick to start combo phase 3 trials with Enhanze. They started phase 3 for Opdivo SC (with Enhaze) for renal cell CA not too long ago and today, they started another Enhanze/Opdivo trial for Melanoma.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HALO News